There are 74 A-share listed Chinese medicine companies, with a total revenue of 171.8 billion yuan in the first half of the year

In recent years, the state has successively introduced heavy policies to vigorously develop the traditional Chinese medicine industry, in this context, the traditional Chinese medicine industry has also achieved rapid development, the scale of enterprises has also expanded, and the concentration of the industry has also been greatly improved
.

It is understood that recently the A-share capital market in the traditional Chinese medicine industry has added a "new army", Enwei Pharmaceutical Co.
, Ltd.
officially landed on the ChiNext board, the issue price is 29.
8 yuan / share, the issue price-earnings ratio is 24.
72 times, the company's stock closed at 43.
73 yuan / share on the same day, an increase of 46.
74%.


With the smooth listing of Enwei Pharmaceutical, the number of listed companies in the A-share Chinese medicine industry (Shenwan Grade II) reached 74, accounting for 16.
05%
of the total number of listed companies in the A-share pharmaceutical and biological industry.

According to the data, these 74 Chinese medicine companies achieved a total revenue of 171.
782 billion yuan in the first half of this year, and a net profit attributable to the mother of 16.
748 billion yuan
.

It is worth mentioning that there are 7 enterprises with operating income of more than 5 billion yuan; The net profit attributable to the mother of 6 enterprises exceeded 1 billion yuan
.

In the first half of the year, Baiyun Mountain achieved revenue and net profit attributable to the mother of 37.
22 billion yuan and 2.
59 billion yuan
, respectively.

China's traditional Chinese medicine industry has a history and inheritance of 5,000 years, the culture of traditional Chinese medicine is broad and profound in the treatment of difficult and chronic diseases has certain advantages, can be applied to cardiovascular and cerebrovascular diseases, respiratory diseases and other 13 categories of treatment
.

In recent years, the development of the traditional Chinese medicine industry has also been paid more and more attention
.

For example, since the 13th Five-Year Plan, the cause of traditional Chinese medicine has been elevated to a national strategy; In July 2017, the "Chinese Medicine Law" was officially implemented, and the Chinese medicine industry entered a new historical period of development and governance according to law; In October 2019, the state put forward 20 more guiding opinions to promote the innovative development of
traditional Chinese medicine.

In May 2021, the State Council issued the "Key Work Tasks for Deepening the Reform of the Medical and Health System in 2021", which clearly regards promoting the revitalization and development of traditional Chinese medicine as one of the key tasks.
.
.
In short, the state has successively introduced a series of policies to vigorously promote the development of the traditional Chinese medicine industry, and the development of traditional Chinese medicine has ushered in new opportunities
.

With the support of favorable policies, the Chinese medicine market has shown a steady growth trend
.

According to the data, in 2013, the market size of China's traditional Chinese medicine industry was 632.
44 billion yuan, and during the period from 2013 to 2017, China's traditional Chinese medicine industry continued to grow at a compound annual growth rate of 5.
7%, and by 2017, the market size reached 790.
11 billion yuan
.

In 2020, the overall scale of China's traditional Chinese medicine market has exceeded 800 billion
.

It is predicted that the Chinese medicine market will exceed 1 trillion yuan in 2024, and the market prospects are very impressive
.

In addition, the industry said that in the future, with the favorable launch of the policy, more innovative Chinese medicine drugs with clinical evidence-based medical value will continue to be promoted and applied, and the space is expected to be further opened
.

The author has learned that in the field of innovative Chinese medicine drugs, another new drug has recently been approved, that is, the 1.
2 class of Chinese medicine innovative drugs Guangqiancao total flavonoid capsules independently developed by Renfu Pharmaceutical, which was recently approved by
the State Drug Administration.

In addition, according to the statistics of relevant databases, from July 1 to September 2, 2022, a total of 9 acceptance numbers of innovative Chinese medicine drugs were undertaken, 8 new drugs of class 1 and 1 new drug of class 2; Of these, 5 are IND applications
.

Among them, the nine accepted innovative Chinese medicines are Qi Huang Mingmu Capsule (Yiling Pharmaceutical), Lychee Nuclear Extract, Lychee Nuclear Capsule (Guangxi University of Traditional Chinese Medicine), Shuanggen Oral Liquid (Chinese Fifth Medical Center of People's Liberation Army General Hospital), Tongxing Granules (Jianmin Pharmaceutical), Shu Liver Relief Capsules (Jishengtang Pharmaceutical), Jiuweihua Spot Pills (Tasly), Compound Wild Chrysanthemum Flavonoids Granules (Zhejiang University of Traditional Chinese Medicine), Anti-allergic Antitussive Granules (Tianjin Ledun Traditional Chinese
。
The industry said that the strong support of national policies, the cultural inheritance of traditional Chinese medicine and the improvement of Chinese people's awareness of traditional Chinese medicine have jointly promoted the wide application
of proprietary Chinese medicine.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.